Physician profile
Catherine Marks
NPI 1801214788
$9,305.82
in general payments reported to CMS, 2019-2025
41 companies · $972 in 2025
The $972 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $698 · 2021: $1,329 · 2022: $2,136 · 2023: $1,860 · 2024: $1,992 · 2025: $972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,682 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,682.30 |
| Education | $140.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,699.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,514.88 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Abbvie INC. | $1,113.92 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $635.00 | 2022-2025 | |
| Amgen INC. | $503.06 | 2022-2025 | Repatha, Otezla, Otezla |
| Dexcom, INC. | $461.16 | 2022-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $438.00 | 2023-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $380.19 | 2020-2025 | Jardiance |
| Redhill Biopharma INC. | $273.22 | 2020-2024 | Talicia, Talicia |
| Janssen Pharmaceuticals, INC | $243.93 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $191.81 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Pfizer INC. | $166.52 | 2023-2025 | |
| Shield Therapeutics INC | $159.69 | 2023-2025 | Accrufer |
| Astrazeneca Pharmaceuticals Lp | $157.01 | 2020-2025 | Airsupra, Fasenra, Breztri |
| Gilead Sciences, INC. | $139.49 | 2019-2024 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $121.57 | 2021-2023 | Gimoti |
| Sumitomo Pharma America, INC. | $103.52 | 2024-2025 | Gemtesa, Myfembree |
| Viiv Healthcare Company | $100.54 | 2023-2024 | Apretude |
| Phathom Pharmaceuticals, INC. | $83.05 | 2024 | Voquezna |
| Vanda Pharmaceuticals INC. | $70.33 | 2022 | |
| Covis Pharma Gmbh | $67.34 | 2022 | |
| Exact Sciences Corporation | $66.46 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $66.27 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Phadia US INC. | $61.75 | 2023-2025 | Immunocap |
| Sanofi-Aventis U.S. LLC | $59.87 | 2024-2025 | |
| Hologic Sales and Service, LLC | $48.98 | 2023 | Aptima |
| Abbott Laboratories | $47.46 | 2023-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $39.33 | 2025 | Venaseal |
| Mayne Pharma Commercial LLC | $32.86 | 2023 | |
| Allergan, INC. | $29.47 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $29.05 | 2024-2025 | Zoryve |
| Ardelyx, INC. | $28.53 | 2024 | Ibsrela |
| Horizon Therapeutics Plc | $28.53 | 2022 | |
| Inari Medical, INC. | $26.07 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Exeltis, USA INC. | $24.96 | 2025 | Slynd |
| Optos, INC. | $18.85 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.53 | 2023 | |
| Mylan Pharmaceuticals INC. | $17.08 | 2021 | |
| Scilex Pharmaceuticals INC. | $16.83 | 2024 | |
| Paratek Pharmaceuticals, INC. | $13.18 | 2024 | Nuzyra |
| Echosens North America, INC. | $9.01 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.